{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:30:39Z","timestamp":1793327439731,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ygyno.2026.10.011","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:50:38Z","timestamp":1792720238000},"page":"144-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Low-grade serous ovarian cancer: 2026 expert consensus report"],"prefix":"10.1016","volume":"214","author":[{"given":"Rachel N.","family":"Grisham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Podder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beryl","family":"Manning-Geist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Vang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren P.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allireza","family":"Alloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Cunliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Nasioudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"DeFazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong-Kwok","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Cheasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ludemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary L.","family":"Balleine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Didsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Girshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Malpica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen I.","family":"Pishas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0010","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e15","article-title":"Trends of low-grade serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.10.011_bb0015","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0020","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.ygyno.2026.02.023","volume":"208","author":"Fader","year":"2026","journal-title":"Gynecol. Oncol."},{"issue":"10324","key":"10.1016\/j.ygyno.2026.10.011_bb0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0030","author":"Administration UFaD"},{"issue":"25","key":"10.1016\/j.ygyno.2026.10.011_bb0035","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of avutometinib\u00b1defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO-25-01348","article-title":"Phase II trial of ribociclib plus letrozole in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum: a GOG partners trial (GOG 3026)","volume":"44","author":"Slomovitz","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0045","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2026.10.011_bb0050","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.011_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv. Anat. Pathol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.10.011_bb0060","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1055\/a-1545-4279","article-title":"2020 WHO classification of female genital tumors","volume":"81","author":"H\u00f6hn","year":"2021","journal-title":"Geburtshilfe Frauenheilkd."},{"issue":"12","key":"10.1016\/j.ygyno.2026.10.011_bb0065","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/PAS.0b013e318181a7ce","article-title":"Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion","volume":"32","author":"Yemelyanova","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0070","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.10.011_bb0075","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma","volume":"31","author":"Malpica","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma","volume":"2","author":"K\u00f6bel","year":"2016","journal-title":"J. Pathol. Clin. Res."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.011_bb0085","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-020-00648-y","article-title":"Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma","volume":"34","author":"Chui","year":"2021","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.011_bb0090","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-2559.2007.02682.x","article-title":"High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour","volume":"50","author":"O'Neill","year":"2007","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.ygyno.2026.10.011_bb0095","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/IGC.0b013e31825e5254","article-title":"Clinical significance of microinvasion in borderline ovarian tumors and its impact on surgical management","volume":"22","author":"Ferrero","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.011_bb0100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/PAS.0000000000000155","article-title":"Evaluation of microinvasion and lymph node involvement in ovarian serous borderline\/atypical proliferative serous tumors. A morphologic and immunohistochemical analysis of 37 cases","volume":"38","author":"Maniar","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.10.011_bb0105","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.pas.0000213294.81154.95","article-title":"The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent","volume":"30","author":"Silva","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.011_bb0110","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/PAS.0000000000000824","article-title":"Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and non-invasive low-grade carcinomas: a population-based clinicopathologic study of 942 cases","volume":"41","author":"Vang","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.10.011_bb0115","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0000000000000692","article-title":"Classification of extraovarian implants in patients with ovarian serous borderline tumors (tumors of low malignant potential) based on clinical outcome","volume":"40","author":"McKenney","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0120","series-title":"Monodermal Teratomas and Somatic-type Tumours Arising from a Dermoid Cyst","first-page":"63","article-title":"WHO classification of tumours of female reproductive organs","author":"Young","year":"2014"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0125","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2025.07.025","article-title":"Ovarian mixed low-and high-grade serous carcinoma as a synchronous or metachronous phenomenon: a clinicopathologic study of 39 cases","volume":"200","author":"Brodsky","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2026.10.011_bb0130","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1158\/1078-0432.CCR-24-3168","article-title":"Clinicopathologic features, molecular landscape, and prognostic implications of ovarian low-grade serous tumors with histologic transformation","volume":"31","author":"Chui","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.011_bb0135","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PGP.0b013e31824ae6f2","article-title":"Low grade serous neoplasms of the ovary with transformation to high grade carcinomas: report of 3 cases","volume":"31","author":"Garg","year":"2012","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/PAS.0000000000001419","article-title":"Clinicopathologic, immunohistochemical, and molecular characteristics of ovarian serous carcinoma with mixed morphologic features of high-grade and low-grade serous carcinoma","volume":"44","author":"Zarei","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.10.011_bb0145","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/PAS.0000000000002294","article-title":"High-grade anaplastic transformation of ovarian serous borderline tumor: a distinctive morphology with abundant dense eosinophilic cytoplasm and dismal prognosis","volume":"48","author":"Zhang","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0150","series-title":"Rare Diseases at FDA","author":"Administration USFaD","year":"2022"},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/his.13071","article-title":"Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma","volume":"70","author":"McIntyre","year":"2017","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.011_bb0160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2010.10.033","article-title":"Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?","volume":"120","author":"Vineyard","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.10.011_bb0165","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12885-018-4242-8","article-title":"Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers","volume":"18","author":"Le Page","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0175","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology\/gynecologic oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0180","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2017.01.002","article-title":"Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study","volume":"144","author":"Rasmussen","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2026.10.011_bb0185","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.10.011_bb0190","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ccell.2025.06.004","article-title":"Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression","volume":"43","author":"Schweizer","year":"2025","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27041774","article-title":"Differential preclinical efficacy of combined CDK4\/6 and MEK inhibition in low-grade serous ovarian carcinoma based on KRAS\/NF1 mutational status","volume":"27","author":"Bittner","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41698-022-00288-2","article-title":"Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression","volume":"6","author":"Cheasley","year":"2022","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J. Pathol."},{"issue":"16","key":"10.1016\/j.ygyno.2026.10.011_bb0210","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/0008-5472.CAN-16-2224","article-title":"EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas","volume":"77","author":"Etemadmoghadam","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12935-019-0725-1","article-title":"Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target","volume":"19","author":"Fernandez","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"35","key":"10.1016\/j.ygyno.2026.10.011_bb0220","doi-asserted-by":"crossref","first-page":"37663","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0225","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2023.09.016","article-title":"Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas","volume":"178","author":"Kobel","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"4\u20135","key":"10.1016\/j.ygyno.2026.10.011_bb0230","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/path.70075","article-title":"Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile","volume":"269","author":"Pishas","year":"2026","journal-title":"J. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.10.011_bb0235","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1158\/0008-5472.CAN-20-2222","article-title":"Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability","volume":"81","author":"Shrestha","year":"2021","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0240","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0245","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1078-0432.CCR-25-3042","article-title":"Molecular profiling and tumor biomarker analysis of GOG281\/LOGS: a positive late-phase trial of trametinib for recurrent\/persistent low-grade serous ovarian carcinoma","volume":"32","author":"Hollis","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.ygyno.2026.10.011_bb0250","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1158\/1078-0432.CCR-23-0621","article-title":"Molecular results and potential biomarkers identified from the phase 3 MILO\/ENGOT-ov11 study of Binimetinib versus physician choice of chemotherapy in recurrent low-grade serous ovarian Cancer","volume":"29","author":"Grisham","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.ygyno.2026.10.011_bb0255","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cncr.34661","article-title":"Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma","volume":"129","author":"Hendrikse","year":"2023","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.011_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102779","article-title":"Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models","volume":"36","author":"Ettorre","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.011_bb0265","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e74","article-title":"FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma","volume":"36","author":"Leung","year":"2025","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0270","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2024.06.008","article-title":"Folate receptor alpha expression in low-grade serous ovarian cancer: exploring new therapeutic possibilities","volume":"188","author":"Manning-Geist","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0275","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","article-title":"Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma","volume":"191","author":"Rushton","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.10.011_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101988","article-title":"Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models","volume":"35","author":"Ettorre","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0285","article-title":"Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma","volume":"13","author":"Al-Aloosi","year":"2023","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.10.011_bb0290","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/1535-7163.MCT-22-0004","article-title":"NOTCH Signaling limits the response of low-grade serous ovarian cancers to MEK inhibition","volume":"21","author":"Llaurado Fernandez","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0295","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12967-022-03820-x","article-title":"Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors","volume":"20","author":"Wong","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105198","article-title":"68O blood ctDNA vs tumor tissue screening for the detection of KRAS mutations in low-grade serous ovarian cancer","volume":"10","author":"Van Nieuwenhuysen","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0305","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2016.11.007","article-title":"A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma","volume":"144","author":"Hannibal","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0310","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae049","article-title":"The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific","volume":"8","author":"Porter","year":"2024","journal-title":"JNCI Cancer Spectr."},{"issue":"2 Pt 1","key":"10.1016\/j.ygyno.2026.10.011_bb0315","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Nickles Fader","year":"2013","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0320","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO study group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.10.011_bb0325","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1016\/S1470-2045(24)00262-6","article-title":"Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE","volume":"25","author":"Morice","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.011_bb0330","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.21873\/anticanres.18163","article-title":"Recurrence and malignant transformation after borderline ovarian tumors: a systematic review and meta-analysis","volume":"46","author":"Taniskidi","year":"2026","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0335","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2026.10.011_bb0340","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.34753","article-title":"Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies","volume":"129","author":"Manning-Geist","year":"2023","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0345","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-74571-2","article-title":"A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma","volume":"17","author":"Cobb","year":"2026","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ygyno.2026.10.011_bb0355","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0360","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2024.08.004","article-title":"The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: a risk-set matched retrospective study","volume":"190","author":"Barakzai","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0365","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2025.09.011","article-title":"Update on contemporary treatment for newly diagnosed stage II-IV low-grade serous ovarian\/peritoneal cancer (LGSOC)","volume":"202","author":"Gershenson","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0375","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2023.03.011","article-title":"Effect of bevacizumab in advanced low grade serous ovarian cancer: data from the MITO 22 trial","volume":"172","author":"Musacchio","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.10.011_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081954","article-title":"CA-125 levels are predictive of survival in low-grade serous ovarian cancer-a multicenter analysis","volume":"14","author":"Wohlmuth","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0385","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0390","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0395","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2026.10.011_bb0400","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib versus physician's choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.10.011_bb0405","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005919","article-title":"GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer","volume":"35","author":"Grisham","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0410","article-title":"Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation","volume":"40","author":"Lima","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0415","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00338","article-title":"Phase II study of dabrafenib and trametinib in patients with Tumors with BRAF(V600E) mutations: updated results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol H","volume":"10","author":"Salama","year":"2026","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0420","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0425","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2017.01.027","article-title":"Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience","volume":"145","author":"Dalton","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.011_bb0430","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0435","series-title":"FDA Approves Pembrolizumab Plus Paclitaxel, with or Without Bevacizumab, for PD-L1-positive Platinum-resistant Epithelial Ovarian Cancer","author":"Administration. UFaD","year":"2026"},{"issue":"10538","key":"10.1016\/j.ygyno.2026.10.011_bb0440","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.011_bb0445","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ygyno.2019.06.014","article-title":"Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: an analysis of five prospective phase II\/III trials of NOGGO metadata base","volume":"154","author":"Canaz","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1095","key":"10.1016\/j.ygyno.2026.10.011_bb0450","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180571","article-title":"Low-grade epithelial ovarian cancer: what a radiologist should know","volume":"92","author":"Elsherif","year":"2019","journal-title":"Br. J. Radiol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0455","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2214\/AJR.17.18254","article-title":"CT features of ovarian tumors: defining key differences between serous borderline tumors and low-grade serous carcinomas","volume":"210","author":"Nougaret","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejro.2015.01.001","article-title":"CT features of low grade serous carcinoma of the ovary","volume":"2","author":"Pannu","year":"2015","journal-title":"Eur. J. Radiol. Open."},{"issue":"8","key":"10.1016\/j.ygyno.2026.10.011_bb0465","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s11604-020-00960-2","article-title":"MR imaging findings of low-grade serous carcinoma of the ovary: comparison with serous borderline tumor","volume":"38","author":"Kawaguchi","year":"2020","journal-title":"Jpn. J. Radiol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0470","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ygyno.2014.02.008","article-title":"Utility of 18F-FDG PET\/CT in follow-up of patients with low-grade serous carcinoma of the ovary","volume":"133","author":"Takeuchi","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.10.011_bb0475","doi-asserted-by":"crossref","first-page":"S689","DOI":"10.1016\/j.jacr.2025.08.033","article-title":"ACR appropriateness criteria&#xae; staging and follow-up of ovarian cancer: 2025 update","volume":"22","author":"Expert Panel on GYN","year":"2025","journal-title":"J. Am. Coll. Radiol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.011_bb0480","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0485","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2026.10.011_bb0490","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00261-016-0701-3","article-title":"Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer","volume":"41","author":"Ganeshan","year":"2016","journal-title":"Abdom Radiol. (NY)."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.011_bb0495","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines(\u2606)","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0500","series-title":"AVMAPKI FAKZYNJA CO-PACK (Avutometinib Capsules; Defactinib Tablets): Prescribing Information","author":"Administration. UFaD","year":"2025"},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.011_bb0505","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation","volume":"29","author":"Jeng-Miller","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0510","series-title":"KISQALI (Ribociclib): Prescribing Information","author":"Administration UFaD","year":"2025"},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0515","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of Abemaciclib-Associated Adverse Events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.011_bb0520","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ygyno.2020.08.015","article-title":"Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients","volume":"159","author":"Bell","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.10.011_bb0525","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.57.1547","article-title":"Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors","volume":"33","author":"Irwin","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.10.011_bb0530","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2017.74.6651","article-title":"Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202","volume":"36","author":"Henry","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9992","key":"10.1016\/j.ygyno.2026.10.011_bb0535","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.011_bb0540","first-page":"311","article-title":"A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors","volume":"29","author":"Carter","year":"2021","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.011_bb0545","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American Menopause society","volume":"30","author":"New Collective A","year":"2023","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.ygyno.2026.10.011_bb0550","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine therapy-induced alopecia in patients with breast cancer","volume":"154","author":"Freites-Martinez","year":"2018","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ygyno.2026.10.011_bb0555","series-title":"Designating an Orphan Product: Drugs and Biological Products","author":"Administration. UFaD","year":"2024"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0560","series-title":"Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review","author":"Administration. UFaD","year":"2023"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0565","series-title":"Commissioner's National Priority Voucher Pilot Program","author":"Administration. UFaD","year":"2026"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0570","series-title":"Drug Trials Snapshot: AVMAPKI FAKZYNJA CO-PACK","author":"Administration. UFaD","year":"2025"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0575","series-title":"Accelerated Approval: Expedited Program for Serious Conditions. Guidance for Industry","author":"Administration. UFaD","year":"2024"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0580","series-title":"Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial Is Underway. Draft Guidance for Industry","author":"Administration. UFaD","year":"2025"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0585","series-title":"Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. Draft Guidance for Industry","author":"Administration. UFaD","year":"2023"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0590","series-title":"Core Patient-Reported Outcomes in Cancer Clinical Trials. Guidance for Industry","author":"Administration. UFaD","year":"2024"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0595","series-title":"Project FrontRunner: Advancing Development of Oncology Therapies to the Early Clinical Setting","author":"Administration UFaD","year":"2024"},{"key":"10.1016\/j.ygyno.2026.10.011_bb0600","series-title":"CDER Patient-Focused Drug Development","author":"Administration. UFaD","year":"2026"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:35:07Z","timestamp":1793324107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":120,"alternative-id":["S0090825826021621"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.10.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-grade serous ovarian cancer: 2026 expert consensus report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}